Douros A, et al. - In patients with type 2 diabetes, researchers evaluated whether adding or switching to sulfonylureas was correlated with an increased risk of myocardial infarction, ischemic stroke, cardiovascular death, all-cause mortality, and severe hypoglycemia, vs staying on metformin monotherapy. Participants in the study were patients with type 2 diabetes beginning metformin monotherapy between 1998 and 2013. Compared with remaining on metformin monotherapy, sulfonylureas as second line drugs were correlated with an increased risk of myocardial infarction, all-cause mortality, and severe hypoglycemia. The findings suggested that continuation of metformin when introducing sulfonylureas was safer than switching.